{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:03:15Z","timestamp":1790877795765,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,21]],"date-time":"2027-08-21T00:00:00Z","timestamp":1818806400000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DK142606"],"award-info":[{"award-number":["R01-DK142606"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cgh.2026.03.038","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:04:39Z","timestamp":1776013479000},"page":"2348-2358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-7514","authenticated-orcid":false,"given":"Michael","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.03.038_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/gutjnl-2022-328515","article-title":"Irritable bowel syndrome: treatment based on pathophysiology and biomarkers","volume":"72","author":"Camilleri","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(25)00051-2","article-title":"Efficacy of gut-brain neuromodulators in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"10","author":"Khasawneh","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14305","article-title":"Pain in irritable bowel syndrome: does anything really help?","volume":"34","author":"BouSaba","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108400","article-title":"Update on treatment of abdominal pain in irritable bowel syndrome: a narrative review","volume":"245","author":"Camilleri","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2009.07.030","article-title":"Comment from the editors: developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes?","volume":"137","author":"Camilleri","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.038_bib6","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","article-title":"Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Ford","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.03.038_bib7","doi-asserted-by":"crossref","first-page":"G584","DOI":"10.1152\/ajpgi.1998.274.3.G584","article-title":"Rectal tone, distensibility, and perception: reproducibility and response to different distentions","volume":"274","author":"Hammer","year":"1998","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/gut.14.2.125","article-title":"Pain from distention of the pelvic colon by inflating a balloon in the irritable colon syndrome","volume":"14","author":"Ritchie","year":"1973","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/gut.31.4.458","article-title":"Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects","volume":"31","author":"Prior","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0016-5085(95)90267-8","article-title":"Altered rectal perception is a biological marker of patients with irritable bowel syndrome","volume":"109","author":"Mertz","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.038_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cgh.2007.12.005","article-title":"Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome","volume":"6","author":"Van der Veek","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1152\/jn.1989.61.5.1001","article-title":"Characteristics of vagal esophageal tension-sensitive afferent fibers in the opossum","volume":"61","author":"Sengupta","year":"1989","journal-title":"Neurophysiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib13","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1152\/jn.1999.82.5.2210","article-title":"Mechanosensitive properties of gastric vagal afferent fibers in the rat","volume":"82","author":"Ozaki","year":"1999","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1152\/jn.1994.71.6.2046","article-title":"Characterization of mechanosensitive pelvic nerve afferent fibers innervating the colon of the rat","volume":"71","author":"Sengupta","year":"1994","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autneu.2009.07.017","article-title":"Molecular basis of mechanosensitivity","volume":"153","author":"Brierley","year":"2010","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114614","article-title":"Analgesic targets identified in mouse sensory neuron somata and terminal pain translatomes","volume":"43","author":"Bangash","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.cgh.2026.03.038_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj9173","article-title":"Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia","volume":"10","author":"Bhuiyan","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.cgh.2026.03.038_bib18","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1111\/ejn.15733","article-title":"Distribution of delta and mu opioid receptor mRNA in rodent dorsal root ganglia neurons","volume":"56","author":"Quirion","year":"2022","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib19","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/j.pain.0000000000001973","article-title":"Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated with RNAscope in situ hybridization","volume":"161","author":"Shiers","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2026.03.038_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj8186","article-title":"Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors","volume":"14","author":"Tavares-Ferreira","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cgh.2026.03.038_bib21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/j.pain.0000000000001217","article-title":"Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq-based resource for pain and sensory neuroscience research","volume":"159","author":"Ray","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2026.03.038_bib22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/cells14100694","article-title":"The identification of opioid receptors and peptide precursors in human DRG neurons expressing pain-signaling molecules confirms their potential as analgesic targets","volume":"14","author":"Mousa","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.cgh.2026.03.038_bib23","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1097\/j.pain.0000000000001846","article-title":"Distribution of functional opioid receptors in human dorsal root ganglion neurons","volume":"161","author":"Moy","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.cgh.2026.03.038_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2036.2000.00757.x","article-title":"Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function","volume":"14","author":"Malcolm","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2982.2009.01263.x","article-title":"Pharmacogenetics of low dose clonidine in irritable bowel syndrome","volume":"21","author":"Camilleri","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1113\/jphysiol.2002.025452","article-title":"Excitation of rat colonic afferent fibres by 5-HT(3) receptors","volume":"544","author":"Hicks","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2036.1998.00375.x","article-title":"Effect of alosetron on responses to colonic distention in patients with irritable bowel syndrome","volume":"12","author":"Delvaux","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib29","article-title":"Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zheng","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.03.038_bib30","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib31","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apt.17426","article-title":"Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial","volume":"57","author":"Gunn","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.34172\/mejdd.2024.386","article-title":"The effect of ondansetron on improvement of symptoms in patients with irritable bowel syndrome with diarrhea domination: a randomized controlled trial","volume":"16","author":"Jafari","year":"2024","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.cgh.2026.03.038_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.70193","article-title":"Clinical characteristics and outcomes of Rome IV diarrhea-predominant irritable bowel syndrome and functional diarrhea prescribed with ondansetron: a real-world study","volume":"37","author":"Sbarigia","year":"2025","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2125.2000.00180.x","article-title":"Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial","volume":"49","author":"Stacher","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2026.03.038_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/gast.2001.26335","article-title":"Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat","volume":"121","author":"Booth","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.038_bib36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1365-2982.2011.01680.x","article-title":"Effects of octreotide on jejunal hypersensitivity triggered by Cryptosporidium parvum intestinal infection in an immunocompetent suckling rat model","volume":"23","author":"Bai","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0022-3565(25)38614-3","article-title":"Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients","volume":"268","author":"Hasler","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib38","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/BF02093780","article-title":"Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone","volume":"39","author":"Bradette","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.03.038_bib39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gut.2010.213108","article-title":"The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome","volume":"59","author":"Klooker","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.gastro.2015.12.034","article-title":"Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome","volume":"150","author":"Wouters","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.038_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gutjnl-2023-331634","article-title":"Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial","volume":"73","author":"Decraecker","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib42","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1523\/JNEUROSCI.20-09-03295.2000","article-title":"Activation of intrinsic afferent pathways in submucosal ganglia of the guinea pig small intestine","volume":"20","author":"Pan","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib43","first-page":"G1139","article-title":"CGRP as a transmitter in the sensory pathway mediating peristaltic reflex","volume":"266","author":"Grider","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib44","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1523\/JNEUROSCI.04-12-03101.1984","article-title":"Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species","volume":"4","author":"Gibson","year":"1984","journal-title":"J Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2005.064063","article-title":"Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat","volume":"55","author":"Delafoy","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.03.038_bib46","doi-asserted-by":"crossref","first-page":"G369","DOI":"10.1152\/ajpgi.00394.2025","article-title":"A pilot, randomized, placebo-controlled trial of rimegepant on visceral sensation and symptoms in non-constipation IBS pain","volume":"330","author":"Halawi","year":"2026","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41575-022-00682-y","article-title":"Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome","volume":"20","author":"Brierley","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2016.09.147","article-title":"Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study","volume":"15","author":"de Vries","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib49","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/apt.13958","article-title":"Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome","volume":"45","author":"Cremon","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/can.2020.0087","article-title":"Effects of cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with symptom-driven dosing","volume":"7","author":"van Orten-Luiten","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.cgh.2026.03.038_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14539","article-title":"Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)","volume":"35","author":"Chang","year":"2023","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib52","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1016\/j.cell.2023.07.007","article-title":"DRG afferents that mediate physiologic and pathologic mechanosensation from the distal colon","volume":"186","author":"Wolfson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2026.03.038_bib53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1476-5381.2010.00682.x","article-title":"Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence","volume":"160","author":"Rollema","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2026.03.038_bib54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.addbeh.2014.11.007","article-title":"Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial","volume":"42","author":"Hooten","year":"2015","journal-title":"Addict Behav"},{"key":"10.1016\/j.cgh.2026.03.038_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2026.03.045","article-title":"Research Letter: an open-label trial of effects of varenicline in non-constipation irritable bowel syndrome and pain","author":"Matar","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib56","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199506223322506","article-title":"The control of pain in peripheral tissue by opioids","volume":"332","author":"Stein","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.03.038_bib57","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2982.2008.01161.x","article-title":"Involvement of kappa-opioid receptors in visceral nociception in mice","volume":"20","author":"Larsson","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib58","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1152\/jn.2000.83.2.963","article-title":"Effects of intracolonic opioid receptor agonists on poly-modal pelvic nerve afferent fibers in the rat","volume":"83","author":"Su","year":"2000","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib59","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1523\/JNEUROSCI.20-15-05874.2000","article-title":"Kappa-opioid receptor agonists modulate visceral nociception at a novel peripheral site of action","volume":"20","author":"Joshi","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib60","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.cgh.2007.07.011","article-title":"Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome","volume":"5","author":"Szarka","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.2008.03730.x","article-title":"Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome","volume":"28","author":"Mangel","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2036.2004.01922.x","article-title":"Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome","volume":"20","author":"Delvaux","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.03.038_bib64","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001789","article-title":"Impact of GLP-1 receptor agonists on whole-gut gastrointestinal motility using wireless motility capsule: a descriptive single-center case series","volume":"12","author":"Cymbal","year":"2025","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.cgh.2026.03.038_bib65","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/2050640620925968","article-title":"Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Wegeberg","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2026.03.038_bib66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.autneu.2006.06.007","article-title":"Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats","volume":"131","author":"Nakade","year":"2007","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib67","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9426014","article-title":"Glucagon-like peptide-1 receptor agonist protects dorsal root ganglion neurons against oxidative insult","volume":"2019","author":"Mohiuddin","year":"2019","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.cgh.2026.03.038_bib68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3344\/kjp.24419","article-title":"Effect of glucagon-like peptide-1 receptor agonist on paclitaxel induced neurotoxicity in dorsal root ganglion neuronal cells in vitro","volume":"38","author":"Jung","year":"2025","journal-title":"Korean J Pain"},{"key":"10.1016\/j.cgh.2026.03.038_bib69","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/biom15050622","article-title":"Therapeutic effects of GLP-1 receptor agonists and dpp-4 inhibitors in neuropathic pain: mechanisms and clinical implications","volume":"15","author":"Kuthati","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.cgh.2026.03.038_bib70","first-page":"1934","article-title":"Glucagon\u2013like peptide\u20131 analogue exendin\u20134 modulates serotonin transporter expression in intestinal epithelial cells","volume":"21","author":"Cui","year":"2020","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cgh.2026.03.038_bib71","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jgh.13808","article-title":"Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats","volume":"33","author":"Nozu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-025-01979-4","article-title":"Advances in GLP-1 receptor agonists for pain treatment and their future potential","volume":"26","author":"He","year":"2025","journal-title":"J Headache Pain"},{"key":"10.1016\/j.cgh.2026.03.038_bib73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molmet.2018.03.004","article-title":"Enterochromaffin 5-HT cells - a major target for GLP-1 and gut microbial metabolites","volume":"11","author":"Lund","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.cgh.2026.03.038_bib74","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2036.2008.03870.x","article-title":"Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study","volume":"29","author":"Hellstr\u00f6m","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.038_bib75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review","volume":"25","author":"Halloum","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.cgh.2026.03.038_bib76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clinre.2016.12.007","article-title":"Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome","volume":"41","author":"Li","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cgh.2026.03.038_bib77","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/00365521.2022.2041084","article-title":"Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics","volume":"57","author":"Touny","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.03.038_bib78","doi-asserted-by":"crossref","first-page":"G507","DOI":"10.1152\/ajpgi.2000.278.4.G507","article-title":"Pathobiology of visceral pain: molecular mechanisms and therapeutic implications II. Genetic approaches to pain therapy","volume":"278","author":"Wood","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cgh.2026.03.038_bib79","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1523\/JNEUROSCI.0703-05.2005","article-title":"The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3","volume":"25","author":"Jones","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib80","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1111\/nmo.12199","article-title":"Peripheral contribution of NGF and ASIC1a to colonic hypersensitivity in a rat model of irritable bowel syndrome","volume":"25","author":"Matricon","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.cgh.2026.03.038_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.611179","article-title":"Upregulation of spinal ASIC1 and NKCC1 expression contributes to chronic visceral pain in rats","volume":"13","author":"Li","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.cgh.2026.03.038_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113565","article-title":"Influence of acid-sensing ion channel blocker on behavioral responses in a zebrafish model of acute visceral pain","volume":"416","author":"Adedara","year":"2022","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.cgh.2026.03.038_bib83","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1016\/j.cgh.2021.08.025","article-title":"Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis","volume":"20","author":"Barberio","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.038_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015591","article-title":"Placebos without deception: a randomized controlled trial in irritable bowel syndrome","volume":"5","author":"Kaptchuk","year":"2010","journal-title":"PLoS One"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526002399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526002399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:04:20Z","timestamp":1787306660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526002399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1542356526002399"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.03.038","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}